biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
05:35 One-time immune cell therapy held MS steady in early trial, maker says✦05:44 Lilly moves a Zepbound add-on that boosted weight loss into big trials✦05:43 Own tumor immune cells plus Keytruda made melanoma vanish on scans in 29%✦05:39 DNA of 8 long-lived bat species ties virus defenses to long life✦05:36 Cholesterol pills cut heart problems in healthy older people, not dementia✦05:32 One-time gene therapy for Duchenne muscle disease met its main trial goal✦05:40 Adding a second immune drug cut death risk 58% in deadly lung cancer trial✦05:27 Custom-made melanoma vaccine cut risk of return or death 42% in big trial✦05:35 One-time immune cell therapy held MS steady in early trial, maker says✦05:44 Lilly moves a Zepbound add-on that boosted weight loss into big trials✦05:43 Own tumor immune cells plus Keytruda made melanoma vanish on scans in 29%✦05:39 DNA of 8 long-lived bat species ties virus defenses to long life✦05:36 Cholesterol pills cut heart problems in healthy older people, not dementia✦05:32 One-time gene therapy for Duchenne muscle disease met its main trial goal✦05:40 Adding a second immune drug cut death risk 58% in deadly lung cancer trial✦05:27 Custom-made melanoma vaccine cut risk of return or death 42% in big trial
← All story threadsSTORY THREAD

Regenxbio's one-time gene therapy for Duchenne.

1 report so far. New developments are added to this thread as they happen.

  1. Oct 25, 2026
    BIG TRIAL MEETS ITS MAIN GOALNo-placebo trial · 31 boys

    One-time gene therapy for Duchenne muscle disease met its main trial goal

    In 31 boys with Duchenne, a single infusion got muscles making a stand-in for a missing protein above a target level. Early walking and standing tests favored treatment.